Compare iShares MSCI ACWI ETF (ACWI) vs Zoetis Inc (ZTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Zoetis Inc — how do they compare? iShares MSCI ACWI ETF trades at $155.71, while Zoetis Inc trades at $75.11 (market cap $31.62B). The key difference: Zoetis Inc pays a 2.81% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| ACWI | ZTS | |
|---|---|---|
52-Week High | $159.97 | $158.80 |
52-Week Low | $128.32 | $71.91 |
Market Cap | — | $31.62B |
Sector | — | Health |
Enterprise Value | — | $38.92B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
Zoetis (ZTS) trades at $76.29, up 1.99% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple class-action lawsuits filed against the company, creating investor uncertainty despite a consensus analyst price target of $101.43.
The stock presents a valuation opportunity with a P/E of 12.36 below industry averages, but faces near-term headwinds from legal challenges and mixed earnings performance. Upside potential exists if the company can overcome litigation concerns and return to consistent earnings beats, while downside risk persists from ongoing legal proceedings and competitive pressures in the animal health market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
